Allos Therapeutics, Inc. (NASDAQ:ALTH)
CAPS Rating:
A biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer.
Growing the love for investing
A biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Major purchase option for a larger pharmaceutical company. Over the past year this company has stabalized itself significantly. FOLOTYN already has approval through the FDA for use in some cancers, and its market will only grow as the drug gains approval for other uses.
Noting that FOLOTYN is already approved for some use makes this a secure biopharm to bet on. Knowing that the drug is in late-stage trials for use in the treatment of other cancers makes this a better bet. Knowing that it will be a one of a kind and most likely will beat all others to market with this kind of drug makes this a great bet. And watching big pharma companies salivate as they wait for the next couple of trials finalize (does anyone else hear the buyout bell ringing?) makes this a great bet for the next 12-24 months.